Clinical Efficacy Of Moxifloxacin And Levofloxacin In The Treatment Of Lower Respiratory Tract Infection

BackgroundLower respiratory tract infection disease is a common disease in the Department of respiration, the current clinical treatment is mainly used for the treatment of antimicrobial agents. Moxifloxacin and levofloxacin as quinolones in clinical verification can improve symptoms of respiratory tract infection, but because of drug resistance of pathogenic bacteria is unknown, and present results also lack of multi center, large sample randomized controlled trials of moxifloxacin and levofloxacin in the treatment efficacy and safety of support, which needing comprehensive analysis of specific randomized controlled trials.ObjectiveTo evaluate the clinical efficacy and safety of moxifloxacin and levofloxacin in the treatment of lower respiratory tract infection, and provide clinical reference for the selection of drugs and treatment measures.Methods106 cases of lower respiratory tract infection were randomly divided into control group and observation group in our hospital during September 2014 to September 2015. The control group using levofloxacin treatment, which observation group were treated with moxifloxacin treatment. To observe and compare the two groups of patients with clinical symptoms disappeared time and in-hospital time, clinical efficacy, bacteriological efficacy and the incidence of adverse reactions.Results(1) The cough disappeared time, wheezing disappearance time, pulmonary rales disappeared time, body temperature returned to normal time, hospitalization time of control group are respectively (5.71+2.32) d, (459+1.93) d, (6.91+2.17) d, (3.81+2.04 d), (7.99+2.32) d, which the observation group are respectively (4.65+1.76) d, (3.35+ 1.24) d, (+5.06 1.58) d, (2.02+1.29 d), (+6.58 166 days). The difference between the two groups was significant, with statistical significance (P< 0.05). (2) The total effective rate was 75.47% of the control group, and 88.68% of the observation group, the two groups compared significantly different, statistically significant (P<0.05). (3) Bacterial clearance rate was 92.11% of control group, while bacterial clearance rate was 70.27% of observation group, compared the two groups were significantly different, statistically significant (P<0.05). (4) Adverse reactions was 15.01% of control group,while adverse reactions was 7.55% of observation group, compared to the two groups were significantly different, statistically significant (P<0.05).Conclusion(1) moxifloxacin and levofloxacin can effectively alleviate the clinical symptoms of the patients with lower respiratory tract infection, and have some clinical and bacteriological efficacy. But adverse reaction of moxifloxacin is lower. (2) Compared with levofloxacin, clinical symptoms improved better in patients with moxifloxacin, symptoms disappeared time and hospital stay are shorter, clinical efficacy and bacterial clearance rate are higher, the incidence of adverse reactions is lower.